This company listing is no longer active
F-star Therapeutics (S4BA) Stock Overview
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
S4BA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
F-star Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.65 |
| 52 Week High | €6.90 |
| 52 Week Low | €2.06 |
| Beta | -0.35 |
| 1 Month Change | 53.94% |
| 3 Month Change | 29.13% |
| 1 Year Change | 168.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 45.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| S4BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 18.8% | -0.1% | 0.1% |
| 1Y | 168.1% | 11.4% | -0.5% |
Return vs Industry: S4BA exceeded the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: S4BA exceeded the German Market which returned -9.5% over the past year.
Price Volatility
| S4BA volatility | |
|---|---|
| S4BA Average Weekly Movement | 25.7% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: S4BA's share price has been volatile over the past 3 months.
Volatility Over Time: S4BA's weekly volatility has increased from 18% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 86 | Eliot Forster | www.f-star.com |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
F-star Therapeutics, Inc. Fundamentals Summary
| S4BA fundamental statistics | |
|---|---|
| Market cap | €156.51m |
| Earnings (TTM) | -€41.70m |
| Revenue (TTM) | €19.74m |
Is S4BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S4BA income statement (TTM) | |
|---|---|
| Revenue | US$21.18m |
| Cost of Revenue | US$0 |
| Gross Profit | US$21.18m |
| Other Expenses | US$65.92m |
| Earnings | -US$44.75m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | -211.32% |
| Debt/Equity Ratio | 17.3% |
How did S4BA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/14 09:31 |
| End of Day Share Price | 2023/03/08 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
F-star Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Patrick Trucchio | H.C. Wainwright & Co. |
| Wangzhi Li | Ladenburg Thalmann & Company |